04/30/2026
Let’s talk about mental health news of the week!
“The US Food and Drug Administration on Friday issued national priority vouchers to three companies studying these psychedelic-based medicines: psilocybin, the active ingredient in “magic mushrooms,” for treatment-resistant depression; psilocybin for major depressive disorder; and methylone, a drug similar to M**A, for post-traumatic stress disorder – better known as PTSD.”
We will be following this one closely. We are very interested in seeing how this pans out!
https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers